Concord Drugs Share Price ₹77 | P/E 51.5

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Concord Drugs

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	11.54	8.79	7.38	12.62	14.47	6.35	11.84	10.77	7.96	13.38	10.07	16.84	35.55
Expenses +	10.80	7.39	5.85	12.06	14.28	5.62	11.05	9.45	7.03	12.44	9.06	15.96	34.13
Operating Profit	0.74	1.40	1.53	0.56	0.19	0.73	0.79	1.32	0.93	0.94	1.01	0.88	1.42
OPM %	6.41%	15.93%	20.73%	4.44%	1.31%	11.50%	6.67%	12.26%	11.68%	7.03%	10.03%	5.23%	3.99%
Other Income +	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.02	0.01
Interest	0.42	0.39	0.39	0.43	0.38	0.37	0.39	0.43	0.53	0.42	0.40	0.30	0.34
Depreciation	0.31	0.38	0.38	0.38	0.39	0.34	0.34	0.37	0.37	0.37	0.34	0.30	0.35
Profit before tax	0.01	0.63	0.77	-0.25	-0.58	0.02	0.07	0.52	0.03	0.15	0.27	0.30	0.74
Tax %	-600.00%	23.81%	31.17%	-4.00%	-39.66%	50.00%	28.57%	57.69%	33.33%	26.67%	29.63%	26.67%	28.38%
Net Profit +	0.07	0.49	0.53	-0.24	-0.35	0.01	0.05	0.22	0.01	0.11	0.19	0.22	0.52
EPS in Rs	0.08	0.53	0.57	-0.24	-0.35	0.01	0.05	0.22	0.01	0.11	0.19	0.17	0.39

Financials of Concord Drugs

Annual income statement trend

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	40.02	50.68	57.43	51.80	48.08	51.34	51.33	58.96	51.31	43.26	36.93	75.85
Expenses +	32.99	42.38	51.93	47.02	44.43	48.00	48.11	53.37	46.97	39.58	33.16	71.61
Operating Profit	7.03	8.30	5.50	4.78	3.65	3.34	3.22	5.59	4.34	3.68	3.77	4.24
OPM %	17.57%	16.38%	9.58%	9.23%	7.59%	6.51%	6.27%	9.48%	8.46%	8.51%	10.21%	5.59%
Other Income +	0.37	0.15	0.09	0.14	0.09	0.12	3.86	0.10	0.01	0.01	0.01	0.03
Interest	2.72	2.57	2.36	1.88	1.59	1.54	1.42	1.68	1.62	1.59	1.72	1.46
Depreciation	3.63	2.91	2.58	2.40	1.71	1.46	1.37	1.76	1.60	1.54	1.42	1.36
Profit before tax	1.05	2.97	0.65	0.64	0.44	0.46	4.29	2.25	1.13	0.56	0.64	1.45
Tax %	33.33%	40.74%	73.85%	50.00%	9.09%	28.26%	23.54%	28.89%	21.24%	25.00%	54.69%	28.28%
Net Profit +	0.70	1.75	0.16	0.32	0.41	0.33	3.28	1.59	0.89	0.42	0.30	1.04
EPS in Rs	0.97	2.42	0.22	0.41	0.52	0.38	3.75	1.82	0.96	0.42	0.30	0.79
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials of Concord Drugs

Capital structure and asset base

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	7.24	7.24	7.24	7.86	7.86	8.74	8.74	8.74	9.32	10.00	10.00	13.18
Reserves	6.07	7.82	11.75	11.46	15.29	14.74	18.02	19.62	22.38	23.82	24.11	35.34
Borrowings +	21.27	19.99	15.43	13.62	9.83	9.57	12.97	16.43	15.63	14.93	16.91	11.61
Other Liabilities +	19.63	17.44	21.11	73.48	49.79	24.96	10.15	11.66	9.31	7.55	7.56	11.72
Total Liabilities	54.21	52.49	55.53	106.42	82.77	58.01	49.88	56.45	56.64	56.30	58.58	71.85
Fixed Assets +	18.32	15.18	13.64	13.51	11.85	10.52	13.83	13.97	12.86	11.63	12.17	11.55
CWIP	0.00	0.00	0.00	0.00	0.29	1.00	0.00	0.55	0.92	1.63	2.00	2.43
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.42	1.62	1.62	1.62
Other Assets +	35.89	37.31	41.89	92.91	70.63	46.49	36.05	41.93	41.44	41.42	42.79	56.25
Total Assets	54.21	52.49	55.53	106.42	82.77	58.01	49.88	56.45	56.64	56.30	58.58	71.85

Financials of Concord Drugs

Operating, investing and financing cash movement

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	1.75	3.05	1.70	6.88	1.19	2.48	1.62	0.77	2.24	1.96	3.16
Cash from Investing Activity +	-1.10	0.23	-1.04	-2.21	-0.34	-0.84	-3.67	-2.44	-2.27	-1.21	-2.32
Cash from Financing Activity +	-0.70	-3.42	-3.94	-4.80	-0.73	-1.79	2.07	1.68	0.05	-0.69	-0.87
Net Cash Flow	-0.06	-0.14	-3.28	-0.13	0.12	-0.15	0.02	0.01	0.03	0.06	-0.02
Free Cash Flow	0.65	3.28	0.66	4.60	0.85	1.63	-2.05	-1.69	1.38	0.94	0.83
CFO/OP	33%	51%	38%	152%	36%	78%	65%	26%	60%	59%	89%

Financials of Concord Drugs

Working capital efficiency and return ratios

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	249.90	183.51	99.46	501.49	367.66	180.94	147.41	141.52	116.31	117.87	125.22	135.37
Inventory Days	65.82	76.39	87.31	156.96	171.81	140.84	100.83	151.64	156.25	202.72	252.62	102.82
Days Payable	207.64	92.05	129.50	559.47	393.02	109.72	26.76	62.25	45.98	35.17	45.03	33.73
Cash Conversion Cycle	108.09	167.85	57.27	98.98	146.44	212.05	221.48	230.90	226.58	285.41	332.82	204.45
Working Capital Days	68.04	113.14	4.00	79.27	102.33	103.37	140.30	112.48	145.12	126.56	134.22	147.78
ROCE %	11.35%	16.06%	8.67%	7.48%	6.16%	6.06%	5.36%	9.30%	5.97%	4.48%	4.73%	5.24%

Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Concord Drugs Share Price & Earnings Call Analysis